AnaptysBio, Inc. (ANAB): Price and Financial Metrics


AnaptysBio, Inc. (ANAB)

Today's Latest Price: $25.77 USD

0.10 (0.39%)

Updated Oct 20 4:00pm

Add ANAB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

ANAB Stock Summary

  • The ratio of debt to operating expenses for Anaptysbio Inc is higher than it is for about just 0.36% of US stocks.
  • ANAB's price/sales ratio is 38.94; that's higher than the P/S ratio of 95.07% of US stocks.
  • With a year-over-year growth in debt of -100%, Anaptysbio Inc's debt growth rate surpasses merely 0% of about US stocks.
  • Stocks that are quantitatively similar to ANAB, based on their financial statements, market capitalization, and price volatility, are CARA, MORF, ENTA, CRBP, and PTGX.
  • ANAB's SEC filings can be seen here. And to visit Anaptysbio Inc's official web site, go to www.anaptysbio.com.

ANAB Stock Price Chart Interactive Chart >

Price chart for ANAB

ANAB Price/Volume Stats

Current price $25.77 52-week high $39.48
Prev. close $25.67 52-week low $10.00
Day low $24.85 Volume 490,900
Day high $26.02 Avg. volume 419,880
50-day MA $17.01 Dividend yield N/A
200-day MA $17.33 Market Cap 703.62M

AnaptysBio, Inc. (ANAB) Company Bio


AnaptysBio Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. The company was founded in 2005 and is based in San Diego, California.


ANAB Latest News Stream


Event/Time News Detail
Loading, please wait...

ANAB Latest Social Stream


Loading social stream, please wait...

View Full ANAB Social Stream

Latest ANAB News From Around the Web

Below are the latest news stories about Anaptysbio Inc that investors may wish to consider to help them evaluate ANAB as an investment opportunity.

AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates

Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance…

GlobeNewswire | August 10, 2020

AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer

Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline AdvancementSAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Paul F. Lizzul, M.D., Ph.D. as Chief Medical Officer. “Paul’s extensive expertise in the development of immune-modulating therapeutics will be instrumental to the advancement of AnaptysBio’s wholly-owned pipeline programs,” said Hamza Suria, president and chief executive officer of AnaptysBio. “Seven AnaptysBio-generated therapeutic antibodies have advanced to the clinic to date, and we will continue leverag...

Yahoo | July 31, 2020

Did Hedge Funds Make The Right Call On AnaptysBio, Inc. (ANAB) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 19, 2020

AnaptysBio expands executive leadership team

AnaptysBio (ANAB) appoints Dennis Mulroy as CFO and Eric Loumeau as COO.Prior to ANAB, Dennis Mulroy has served as CFO of La Jolla Pharmaceutical Company, Taxus Cardium Pharmaceuticals Group, Molecular Imaging and SeraCare Life Sciences.Eris Loumeau joined AnaptysBio in Aug. 2018 as General Counsel and has also served as interim...

Seeking Alpha | July 15, 2020

AnaptysBio Expands Executive Leadership Team

SAN DIEGO, July 15, 2020 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging.

Yahoo | July 15, 2020

Read More 'ANAB' Stories Here

ANAB Price Returns

1-mo 63.00%
3-mo 25.89%
6-mo 59.37%
1-year -31.13%
3-year -60.15%
5-year N/A
YTD 58.58%
2019 -74.53%
2018 -36.67%
2017 N/A
2016 N/A
2015 N/A

Continue Researching ANAB

Here are a few links from around the web to help you further your research on Anaptysbio Inc's stock as an investment opportunity:

Anaptysbio Inc (ANAB) Stock Price | Nasdaq
Anaptysbio Inc (ANAB) Stock Quote, History and News - Yahoo Finance
Anaptysbio Inc (ANAB) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7123 seconds.